Welcome to our dedicated page for Alkermes plc news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes plc stock.
Alkermes Inc. plc (NASDAQ: ALKS) is a global biopharmaceutical company dedicated to developing innovative medicines for treating central nervous system (CNS) diseases. Headquartered in Dublin, Ireland, Alkermes has a significant presence in the United States with a research and development center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. The company’s mission is to leverage its proprietary technologies to create and commercialize pharmaceutical products that address unmet medical needs in conditions such as schizophrenia, depression, addiction, and multiple sclerosis.
Alkermes’ diversified product portfolio includes notable medications like LYBALVI®, ARISTADA®, and VIVITROL®. These products are pivotal in the treatment of mental health disorders and substance abuse, demonstrating the company's commitment to enhancing patient outcomes. LYBALVI®, a combination of olanzapine and samidorphan, is used for treating schizophrenia and bipolar I disorder. ARISTADA® is an extended-release injectable suspension for schizophrenia, and VIVITROL® is used for alcohol and opioid dependence.
The company's robust clinical pipeline features breakthrough candidates such as ALKS 2680, an investigational orexin 2 receptor agonist targeting narcolepsy. Recent study results announced in early 2024 have shown promising improvements in wakefulness for patients with narcolepsy type 2 and idiopathic hypersomnia, validating the potential of ALKS 2680 to address critical gaps in treatment.
Alkermes has also engaged in significant corporate developments, including the sale of its Athlone, Ireland facility to Novo Nordisk, aimed at increasing operational efficiency. Financially, the company reported total revenues of $1.66 billion for 2023, with a net income of $356 million, emphasizing strong growth and profitability. The company's strategic focus on neuroscience and operational efficiency is expected to drive sustained profitability and innovation in treating CNS disorders.
For more detailed information about Alkermes’ products, clinical trials, and corporate strategies, you can visit their official website at www.alkermes.com.
Alkermes announces positive topline results from the ENLIGHTEN-Early phase 3b study of LYBALVI (olanzapine and samidorphan) in young adults (ages 16-39) with schizophrenia, schizophreniform disorder, or bipolar I disorder. The study met its primary endpoint, showing less weight gain in patients treated with LYBALVI (mean: 4.91%) compared to olanzapine (mean: 6.77%, p=0.012) at week 12. Secondary endpoints also favored LYBALVI in weight gain percentages and symptom severity. Safety profiles were consistent with prior studies, with a majority of patients completing the trial.
Alkermes plc (Nasdaq: ALKS) will conduct a conference call on February 16, 2022, at 8:00 a.m. ET to discuss its fourth quarter and year-end 2021 financial results. The call will provide insights into the company's financial expectations for 2022 and include an operational update. Investors can access the webcast and slides via the Investors section on Alkermes' website. Dial-in details for U.S. and international callers are provided. A replay will be available shortly after the event.
Alkermes plc (Nasdaq: ALKS) announced its presentation of clinical data on nemvaleukin alfa, an investigational IL-2 variant immunotherapy, at the ASCO Gastrointestinal Cancers Symposium from Jan. 20-22, 2022. The poster will feature findings from the ARTISTRY-1 phase 1/2 study, evaluating nemvaleukin's efficacy and tolerability alone and with KEYTRUDA in advanced GI cancers. The abstract number is 659, presented by Dr. Ulka N. Vaishampayan. Nemvaleukin aims to enhance tumor-killing immune cells while minimizing immunosuppression.
Alkermes plc (Nasdaq: ALKS) will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 11:15 a.m. EST. CEO Richard Pops will lead the presentation, followed by a Q&A session. The event will be accessible via live webcast on the company's investor relations page and archived for 14 days. Alkermes is focused on developing innovative medicines in neuroscience and oncology, with a portfolio aimed at addiction, schizophrenia, and bipolar I disorder.
Alkermes plc (Nasdaq: ALKS) announced its participation in the fourth annual Evercore ISI HealthCONx Conference on December 2, 2021, at 10:30 a.m. ET. The event will be accessible under the Investors section of Alkermes' website and archived for 14 days. Alkermes is a global biopharmaceutical company focused on developing innovative medicines in neuroscience and oncology, with a pipeline targeting neurodegenerative disorders and cancer.
Alkermes plc (Nasdaq: ALKS) has appointed Cato T. Laurencin, M.D., Ph.D., as a new independent director to its Board. Dr. Laurencin is a distinguished academic and pioneer in regenerative engineering with a strong focus on public health and social justice. His appointment, welcomed by CEO Richard Pops, is expected to enhance the company’s innovation and shareholder value creation strategies. Alex Denner of Sarissa Capital views this as a positive outcome for shareholders, anticipating a fresh perspective and improved operational excellence.
Alkermes plc (Nasdaq: ALKS) has initiated a Phase 1 study for ALKS 1140, an investigational HDAC inhibitor aimed at treating neurodegenerative disorders. The study's first subject has been dosed, targeting safety and tolerability in healthy adults. ALKS 1140 is designed to enhance synaptic function, addressing significant unmet medical needs. The trial will involve up to 80 volunteers in Australia and assess pharmacokinetics and pharmacodynamics, marking a crucial step in Alkermes’ clinical program.
Alkermes plc (Nasdaq: ALKS) will participate in a fireside chat at the Stifel Virtual Healthcare Conference on November 16, 2021, at 9:20 a.m. ET. Investors can access the presentation via the Investors tab on the company's website. Alkermes focuses on developing innovative medicines in neuroscience and oncology, with a range of products targeting addiction, schizophrenia, and bipolar I disorder. The company has R&D facilities in Massachusetts and manufacturing sites in Ireland and Ohio.
On Nov. 8, 2021, Alkermes plc (Nasdaq: ALKS) announced it received notices of partial termination from Janssen Pharmaceutica regarding two license agreements concerning the use of Alkermes' NanoCrystal® technology. This impacts royalties from products like INVEGA SUSTENNA® and INVEGA TRINZA®. While Janssen claims it does not use this technology, Alkermes disputes this and will explore enforcement options. CFO Iain Brown indicated that while cash flow could be adversely impacted in the coming years, the company's long-term outlook remains unchanged, with expected growth from products like LYBALVI®, ARISTADA®, and VUMERITY®.
FAQ
What is the current stock price of Alkermes plc (ALKS)?
What is the market cap of Alkermes plc (ALKS)?
What does Alkermes Inc. plc specialize in?
What are some key products of Alkermes?
Where is Alkermes headquartered?
What recent achievements has Alkermes announced?
How did Alkermes perform financially in 2023?
What strategic moves has Alkermes made recently?
What is ALKS 2680?
What initiatives support Alkermes' commitment to mental health?
How can I get more information about Alkermes?
What partnerships or collaborations is Alkermes involved in?
